David A. Tuveson, M.D., Ph.D.

Professor and Director of CSHL Cancer CenterCold Spring Harbor Laboratory

Dr. Tuveson obtained a bachelor’s degree in chemistry at M.I.T. and medical and doctoral degrees at The Johns Hopkins University. He was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Partners Cancer Care. During his postdoctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri, and created several Kras- dependent mouse cancer models with Tyler Jacks. His lab also generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania.  Subsequently he moved to the University of Cambridge, UK, to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently being evaluated in the clinic. In 2012, Dr. Tuveson was recruited back to the US to direct the Cancer Therapeutics Initiative within CSHL’s Cancer Center. He continues to practice medical oncology with an adjunct appointment at Memorial Sloan-Kettering Cancer Center and a clinical affiliation at Northwell Health. Dr. Tuveson serves on the Scientific Advisory Council for Stand up to Cancer and the SAB of the Georg Speyer Haus.  Dr. Tuveson’s honors include the Rita Allen Foundation Scholar Award, the Waldenstrom Award (2014), the Hamdan Award (2016), and election to the American Society of Clinical Investigation (2016).  Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at CSHL, the head of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, and is also the Lustgarten Foundation’s Director of Research.  

Dr. Tuveson’s research and clinical focus is pancreatic cancer, a lethal malignancy that continues to lack effective clinical solutions. His research at CSHL is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches, based in part on pancreatic organoid technology that he has pioneered and participates on many national and international committees and organizations to bring scientific findings into clinical evaluation for pancreatic cancer patients. His laboratory established a methodology for drug development in our mouse pancreatic cancer models, and thereby identified several therapeutic opportunities regarding stromal targeting that are now undergoing clinical evaluation. Furthermore, his group discovered several fundamental aspects of tumor progression including redox regulation and the role of genes in metastasis; developed human organoid models of pancreatic cancer, and using these organoids they have explored the basic biology of pancreatic cancer and investigated new therapeutic strategies.
Sessions
Jan 01 12:00 AM